Accéder au contenu
Merck

HCVD1MAG-67K

MILLIPLEX® Human Cardiovascular Disease Panel

Configurable Human CVD 12-Plex Panel 1

Synonyme(s) :

CVD assay snapshot, CVD multiplex product sheet, cardiac injury biomarker panel, heart failure detection kit, human CVD assay overview, human cardiac biomarker info, human cardiovascular panel summary, human cardiovascular research tool, vascular inflammation marker listing

Se connecter pour consulter les tarifs organisationnels et contractuels.

A propos de cet article

UNSPSC Code:
12161503
NACRES:
NA.84
eCl@ss:
32161000

Principaux documents

Voir toute la documentation
Service technique
Besoin d'aide ? Notre équipe de scientifiques expérimentés est là pour vous.
Laissez-nous vous aider

species reactivity

human

Quality Level

200

assay range

accuracy: 100%
(CK-MB), accuracy: 102%
(LIGHT), accuracy: 102%
(Oncostatin (OSM)), accuracy: 103%
(CXCL6/GCP-2), accuracy: 96%
(FABP3), accuracy: 96%
(Placental Growth Factor (PlGF)), accuracy: 97%
(NT proBNP), standard curve range: 137.2-100,000 pg/mL
(FABP3), standard curve range: 2.7-2,000 pg/mL
(Placental Growth Factor (PlGF)), standard curve range: 34.3-25,000 pg/mL
(NT proBNP, CXCL16, Endocan-1 (ESM-1), LIGHT), standard curve range: 6.9-5,000 pg/mL
(CXCL6, Oncostatin (OSM)), standard curve range: 68.6-50,000 pg/mL
(BNP, CK-MB, Troponin I (TnI)), standard curve range: 685.9-500,000 pg/mL
(FABP4), inter-assay cv: <20%
intra-assay cv: <10%

technique(s)

multiplexing: suitable

input

serum plasma (Cell culture, cell culture supernatants)

packaging

pkg of 1 ea

manufacturer/tradename

Milliplex®

detection method

fluorometric (Luminex® xMAP® technology)

shipped in

wet ice

storage temp.

2-8°C

Catégories apparentées

General description

Cardiovascular disease involves a complex network of biological processes including myocardial stress, vascular inflammation, endothelial dysfunction, and metabolic imbalance. This set of biomarkers—BNP, NT-proBNP, CK-MB, CXCL6/GCP-2, CXCL16, Endocan-1 (ESM-1), FABP3, FABP4, LIGHT, Oncostatin-M (OSM), Placental Growth Factor (PlGF), and Troponin I (TnI)—captures key indicators of cardiac injury, inflammation, and vascular remodeling. These analytes are widely studied in the context of heart failure, atherosclerosis, myocardial infarction, and cardiometabolic disorders, making them essential for translational and clinical cardiovascular research.

Application

MILLIPLEX® Qualified assays undergo rigorous assay development, verification, and Quality Control testing to achieve optimal performance. Simultaneously analyze up to 12 analytes in human serum, plasma, or cell/tissue culture supernatants.

Analytes included: BNP, NT-proBNP, CK-MB, CXCL6/GCP-2, CXCL16, Endocan-1 (ESM-1), FABP3, FABP4, LIGHT, Oncostatin-M (OSM), Placental Growth Factor (PlGF), Troponin I (TnI)

Assay Characteristics: Refer to assay protocol for details on cross-reactivity, sensitivity, precision, and accuracy.

Features and Benefits

Features:
  • Targets biomarkers associated with cardiac stress, vascular inflammation, and endothelial dysfunction
  • Includes 12 analytes relevant to heart failure, myocardial injury, and atherosclerosis
  • Multiplex format enables simultaneous detection from minimal sample volume
  • Compatible with human serum, plasma, and cell/tissue culture supernatants
  • Designed for research in cardiovascular disease, metabolic syndrome, and inflammatory conditions
Benefits:
  • Provides a comprehensive profile of cardiovascular and inflammatory biomarkers
  • Supports investigation of disease mechanisms in heart failure, ischemia, and vascular remodeling
  • Facilitates evaluation of therapeutic interventions and biomarker-based risk stratification
  • Enables high-throughput analysis with reduced sample and reagent use
  • Delivers reproducible, sensitive results for translational and clinical research

Legal Information

Luminex is a registered trademark of Luminex Corp
MILLIPLEX is a registered trademark of Merck KGaA, Darmstadt, Germany
xMAP is a registered trademark of Luminex Corp

Disclaimer

For research use only. Not for use in diagnostic procedures.

Label License/Sticker for Assay Product:

By opening the packaging containing this Assay Product (which contains fluorescently labeled microsphere beads authorized by Luminex Corporation) or using this Assay Product in any manner, you are consenting and agreeing to be bound by the End User Terms and Conditions and the End User License Agreement available at http://support.diasorin.com/end-user-terms-and-conditions/. If you do not agree to all of the terms and conditions, you must promptly return this Assay Product for a full refund prior to using it in any manner.

signalword

Danger

Hazard Classifications

Acute Tox. 4 Dermal - Acute Tox. 4 Inhalation - Acute Tox. 4 Oral - Aquatic Chronic 2 - Eye Dam. 1 - Skin Sens. 1 - STOT RE 2

target_organs

Respiratory Tract

Classe de stockage

10 - Combustible liquids

wgk

WGK 3

Certificats d'analyse (COA)

Recherchez un Certificats d'analyse (COA) en saisissant le numéro de lot du produit. Les numéros de lot figurent sur l'étiquette du produit après les mots "Lot" ou "Batch".

Déjà en possession de ce produit ?

Retrouvez la documentation relative aux produits que vous avez récemment achetés dans la Bibliothèque de documents.

Consulter la Bibliothèque de documents

Luca Di Antonio et al.
Scientific reports, 8(1), 15631-15631 (2018-10-26)
The aim of the study was to assess retinal vascular changes using optical coherence tomography angiography (OCTA) and aqueous humour changes of vascular endothelial growth factor (VEGF) and placental growth factor (PIGF) levels in treatment-naïve myopic choroidal neovascularization (mCNV) after
Andrew J Swift et al.
Thorax, 76(10), 1032-1035 (2021-02-27)
End points that are repeatable and sensitive to change are important in pulmonary arterial hypertension (PAH) for clinical practice and trials of new therapies. In 42 patients with PAH, test-retest repeatability was assessed using the intraclass correlation coefficient and treatment
Li-Rong Yu et al.
Experimental biology and medicine (Maywood, N.J.), 243(3), 248-255 (2017-12-12)
Cancer treatment with doxorubicin (DOX) can induce cumulative dose-dependent cardiotoxicity. Currently, there are no specific biomarkers that can identify patients at risk during the initial doses of chemotherapy. The aim of this study was to examine plasma cytokines/chemokines and potential
Seungwon An et al.
The ocular surface, 17(3), 589-614 (2019-04-10)
To investigate the role of neutrophil extracellular traps (NETs) and NET-associated proteins in the pathogenesis of oGVHD and whether dismantling of NETs with heparin reduces those changes. Ocular surface washings from oGVHD patients and healthy subjects were analyzed. Isolated peripheral
Kévin Contrepois et al.
Cell, 181(5), 1112-1130 (2020-05-30)
Acute physical activity leads to several changes in metabolic, cardiovascular, and immune pathways. Although studies have examined selected changes in these pathways, the system-wide molecular response to an acute bout of exercise has not been fully characterized. We performed longitudinal
Afficher tous les articles scientifiques apparentés

Numéro d'article de commerce international

RéférenceGTIN
HCVD1MAG-67K-0104053252798191
HCVD1MAG-67K-0304053252798214
HCVD1MAG-67K-0904053252798276
HCVD1MAG-67K-0704053252798252
HCVD1MAG-67K-0804053252798269
HCVD1MAG-67K-1004053252798283
HCVD1MAG-67K-1204053252798306
HCVD1MAG-67K-0204053252798207
HCVD1MAG-67K-0404053252798221
HCVD1MAG-67K-1104053252798290
HCVD1MAG-67K-0504053252798238
HCVD1MAG-67K-0604053252798245

Notre équipe de scientifiques dispose d'une expérience dans tous les secteurs de la recherche, notamment en sciences de la vie, science des matériaux, synthèse chimique, chromatographie, analyse et dans de nombreux autres domaines..

Contacter notre Service technique